Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS)
- PMID: 10335932
- DOI: 10.1007/s005200050244
Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS)
Abstract
Normative data and trends for a disease- and site-specific quality of life (QL) instrument for individuals with lung cancer, the Lung Cancer Symptom Scale (LCSS), are presented to facilitate the user's interpretation of test scores. Data for patients enrolled in two large, identical, randomized trials of a new combination chemotherapy regimen for patients with stages III and IV non-small-cell lung cancer (NSCLC) were combined into one dataset (n = 673). For these patients with a Karnofsky performance status (KPS) of 60-100%, QL had been prospectively measured at baseline, day 29 and every 6 weeks thereafter. Descriptive statistics for the LCSS are presented for three time points (baseline, day 29 and day 71) and for specific demographic and disease-related characteristics (age, gender, race, performance status and stage of disease) to provide expected values and their variability during chemotherapy. Data from a small dataset of 63 NSCLC inpatients with KPS scores of 20-50% are also presented for a comparison sample of supportive care for inpatients and hospice patients. For the 673 NSCLC patients at baseline there were no significant differences in QL by age, gender, or race. Major presenting lung cancer symptoms at baseline for this combined sample were dyspnea 87%, cough 86%, pain 81%, loss of appetite 75%, and hemoptysis 41%. Of these patients, 81% had three or more presenting symptoms at baseline (2% had no symptoms; 5%, one symptom; 12%, two symptoms; 18%, three symptoms; 27%, four symptoms; and 36%, five symptoms). The mean LCSS baseline score (best = 0; worst = 100) was 26.56 (SD 16.10). The mean scores for day 29 and day 71 were 25.46 (SD 16.52) and 25.30 (SD 16.93), respectively, but follow-up assessments on progressers were not obtained. Stage III patients had a mean LCSS score of 23.7 (SD 15.1), whereas stage IV patients reported a mean LCSS score of 27.3 (SD 16.3). The mean LCSS score for the group with KPS 60-70% was 34.8 (SD 15.5), and that for the group with KPS 80-100% was 23.3 (SD 15.1). The mean LCSS score for the lower performance group, with KPS scores of 20-50% at baseline, was 46.85 (SD 17.65).
Similar articles
-
Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS).Support Care Cancer. 2009 Mar;17(3):307-13. doi: 10.1007/s00520-008-0489-y. Epub 2008 Sep 10. Support Care Cancer. 2009. PMID: 18781341
-
Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial.Lung Cancer. 2004 Feb;43(2):183-94. doi: 10.1016/j.lungcan.2003.09.001. Lung Cancer. 2004. PMID: 14739039 Clinical Trial.
-
Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale.Cancer. 1994 Apr 15;73(8):2087-98. doi: 10.1002/1097-0142(19940415)73:8<2087::aid-cncr2820730813>3.0.co;2-x. Cancer. 1994. PMID: 8156514
-
Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS).Support Care Cancer. 1994 Jul;2(4):213-22. doi: 10.1007/BF00365725. Support Care Cancer. 1994. PMID: 8087439 Review.
-
Comparison of instruments for measuring quality of life in patients with lung cancer.Semin Oncol. 1996 Apr;23(2 Suppl 5):31-40. Semin Oncol. 1996. PMID: 8610235 Review.
Cited by
-
Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial.Trials. 2021 Mar 17;22(1):214. doi: 10.1186/s13063-021-05169-w. Trials. 2021. PMID: 33731199 Free PMC article.
-
A comparison of visual analogue and numerical rating scale formats for the Lung Cancer Symptom Scale (LCSS): does format affect patient ratings of symptoms and quality of life?Qual Life Res. 2005 Apr;14(3):837-47. doi: 10.1007/s11136-004-0833-8. Qual Life Res. 2005. PMID: 16022076
-
The association of depressive symptoms, personality traits, and sociodemographic factors with health-related quality of life and quality of life in patients with advanced-stage lung cancer: an observational multi-center cohort study.BMC Cancer. 2020 May 18;20(1):431. doi: 10.1186/s12885-020-06823-3. BMC Cancer. 2020. PMID: 32423432 Free PMC article.
-
Co-morbidity and functional deficits independently contribute to quality of life before chemotherapy in elderly cancer patients.Support Care Cancer. 2007 Sep;15(9):1097-104. doi: 10.1007/s00520-007-0228-9. Epub 2007 Feb 21. Support Care Cancer. 2007. PMID: 17318590
-
Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics.Pharmacoeconomics. 2001;19(8):855-63. doi: 10.2165/00019053-200119080-00007. Pharmacoeconomics. 2001. PMID: 11596837
MeSH terms
LinkOut - more resources
Full Text Sources
Medical